Screening for sleep apnea and hormone disorders in persistent atrial fibrillation
Checks adults with persistent atrial fibrillation for sleep apnea and aldosterone disorders.
Plain-language title generated from the registry record
Registry title: Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
Key facts
- Where
- Augsburg, GermanySee the site
Where in Germany
- University Hospital AugsburgAugsburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christina Berr. MD
- Trial code
- NCT07857044
- Record updated
- 5 October 2026
- Original description
Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.Read full original descriptionShow less
Left-atrial Fibrosis in Persistent Atrial Fibrillation, Sleep Apnoe and Primary Aldosteronism
Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.
Inclusion: persistent atrial fibrillation, eligible for ablation; BMI 19-40.
Exclusion: medication interfereing with measurements of atrial fibrosis; valvular atrial fibrillation; formerly ablation; known or treated comorbidities (OSAS, PA).